CTI Clinical Trial and Consulting Services (CTI) has joined the Alliance for Regenerative Medicine (ARM), an advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. According to their website, “ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations.” CTI is one of two clinical research organizations currently a part of ARM.
“CTI is excited to be a part of this incredible group of thought leaders in stem cell and regenerative medicine,” according to Timothy J. Schroeder, President and CEO of CTI. “Regenerative medicine will transform the treatment of many diseases over the next several years, and the group of innovative members in ARM will lead the way. We are looking forward to our partnership with the Alliance for Regenerative Medicine.”